Regulus Therapeutics Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.15 | -$0.15 | -$0.15 |
Q2 2024 | 4 | -$0.18 | -$0.17 | -$0.17 |
Q3 2024 | 1 | -$0.17 | -$0.17 | -$0.17 |
Q1 2025 | 2 | -$0.20 | -$0.20 | -$0.20 |
Q2 2025 | 2 | -$0.20 | -$0.20 | -$0.20 |
Q3 2025 | 2 | -$0.22 | -$0.22 | -$0.22 |
Q4 2025 | 2 | -$0.23 | -$0.23 | -$0.23 |
Q1 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
Q2 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
Q3 2026 | 1 | -$0.27 | -$0.27 | -$0.27 |
Q4 2026 | 1 | -$0.27 | -$0.27 | -$0.27 |
Regulus Therapeutics Inc. Earnings Date And Information
Regulus Therapeutics Inc. last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.17 earnings per share for the quarter, missing analysts' consensus estimates of $-0.17 by $0. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Regulus Therapeutics Inc. has generated $-2 earnings per share over the last year ($-1.58 diluted earnings per share) and currently has a price-to-earnings ratio of -2.88. Regulus Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Regulus Therapeutics Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2024 | Q2 2024 | -$0.17 | -$0.17 | 0 | $0 | $0 |
05/09/2024 | Q1 2024 | -$0.15 | -$0.29 | -0.14 | $0 | |
03/21/2024 | Q4 2023 | -$0.40 | -$0.40 | 0 | $302,000 | |
11/09/2023 | Q3 2023 | -$0.36 | -$0.40 | -0.04 | $0 | |
08/08/2023 | Q2 2023 | -$0.39 | -$0.37 | 0.02 | $0 | |
05/11/2023 | Q1 2023 | -$0.41 | -$0.42 | -0.01 | $0 | |
03/23/2023 | Q4 2022 | -$0.49 | -$0.40 | 0.09 | $0 | |
11/10/2022 | Q3 2022 | -$0.50 | $0 | |||
08/11/2022 | Q2 2022 | -$0.46 | -$0.50 | -0.04 | $0 | |
05/12/2022 | Q1 2022 | -$0.46 | $0 | |||
03/10/2022 | Q4 2021 | -$0.67 | $0 | |||
11/10/2021 | Q3 2021 | -$0.99 | $6,000 | $0 | ||
08/10/2021 | Q2 2021 | -$0.80 | -$0.78 | 0.02 | $0 | |
05/13/2021 | Q1 2021 | -$0.84 | $0 | |||
03/09/2021 | Q4 2020 | -$1.00 | -$0.28 | 0.72 | $5.00 M | |
11/05/2020 | Q3 2020 | -$2.00 | -$0.40 | 1.6 | $339,333 | $5.00 M |
08/13/2020 | Q2 2020 | -$2.10 | -$2.33 | -0.23 | $2.50 M | $0 |
05/14/2020 | Q1 2020 | -$0.10 | -$2.47 | -2.37 | $6,000 | |
03/12/2020 | Q4 2019 | -$2.40 | -$2.34 | 0.06 | $18,000 | |
11/12/2019 | Q3 2019 | -$2.90 | -$2.60 | 0.3 | $9,000 | $18,000 |
Regulus Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Regulus Therapeutics Inc.'s earnings date?
Regulus Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
How can I listen to Regulus Therapeutics Inc.'s earnings conference call?
The conference call for Regulus Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Regulus Therapeutics Inc.'s conference call transcript?
The conference call transcript for Regulus Therapeutics Inc.'s latest earnings report can be read online.
-
How much profit does Regulus Therapeutics Inc. generate each year?
Regulus Therapeutics Inc. (:RGLS) has a recorded net income of $0. Regulus Therapeutics Inc. has generated $-1.58 earnings per share over the last four quarters.
-
What is Regulus Therapeutics Inc.'s price-to-earnings ratio?
Regulus Therapeutics Inc. (:RGLS) has a price-to-earnings ratio of -2.88 and price/earnings-to-growth ratio is -0.19.